Preparation and characteristic of lactose‐oleoylchitosan and the application of its self‐aggregates as drug delivery system

Abstract

Amphiphilic polymers lactose-oleoylchitosan (Lac-OCH) with different degree of substitution (DS) of lactose were prepared. The chemical structure of the new chitosan derivative was tested and verified. The rheological features including solubility and viscosity of Lac-OCH were investigated. The introduction of hydrophilic group lactose could improve the solubility of the polymer and Lac-OCH was soluble in acetic acid solution under pH 7.0. The viscosity of Lac-OCH decreased a little along with the increasing of DS of lactose. Lac-OCH with high DS, middle DS, and low DS of lactose possessed small critical aggregation concentration value, and the critical aggregation concentration value rised along with the increasing of DS of lactose. However, the affect was not obvious. In brief, the CAC values were 0.0325, 0.0340, and 0.0344 mg/ mL corresponding to the samples of low DS, middle DS, and high DS. Lac-OCH, obtained by hydrophilic modified using lactose, could also form self-assembled nanoparticles by oil/water (O/W) emulsification method comparing with OCH. The Lac-OCH nanoparticles showed dense, axiolitic texture, and the average diameter was approximate 200 nm. The sustained-release characteristics of Lac-OCH nanoparticles were studied using Doxorubicin as model drug. The results revealed the promising potential of amphiphilic Lac-OCH as drug carrier.

Improved pH-responsive amphiphilic carboxymethyl-hexanoyl chitosan–poly(acrylic acid) macromolecules for biomedical applications

“…[4][5][6][7] A vast number of natural and synthetic polymers have been used to prepare nanocarriers for cancer therapy. [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] Among them, chitosan (CS) is particularly attractive owing to its biological activity, low toxicity, biocompatibility and biodegradability. Self-aggregated nanoparticles or micelles based on amphiphilic chitosan derivatives, such as glycol chitosan carrying 5b-cholanic acid, 14 glycidol-chitosan-deoxycholic acid, 15 hydrotropic oligomerconjugated glycol chitosan 16 and 6-mercaptopurine-carboxymethyl chitosan, 17 have been extensively reported for applications in, for instance, delivering conventional drugs, 15 peptides, 14 and DNA 18 for cancer therapy.…”

Chitosan/OA nanoparticle as delivery system for celecoxib: Parameters affecting the particle size, encapsulation, and release

“…The CAC of Ch/OA taken from the break point of the intersection of the lines was 0.020 mg mL −1 . This concentration is lower in comparison with some systems of chitosan‐fatty acids and surfactants, which is indicative of the amphiphilic character of this chitosan derivative that provides stability of self‐aggregates in dilute conditions …”